SJEPD015_D.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 2.72
- e1_e2
- E2
- umap1_2d
- -6.668083136
- umap2_2d
- -0.268861078
- umap1_3d
- 0.794099977
- umap2_3d
- 3.35997864
- umap3_3d
- 0.908951401
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.330
- CHOLESTEROL_HOMEOSTASIS+0.290
- FATTY_ACID_METABOLISM+0.290
- COAGULATION+0.260
- KRAS_SIGNALING_DN+0.260
- MYOGENESIS+0.190
- XENOBIOTIC_METABOLISM+0.190
- SPERMATOGENESIS+0.180
- TNFA_SIGNALING_VIA_NFKB+0.180
- ANGIOGENESIS+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.350
- INTERFERON_GAMMA_RESPONSE-0.260
- MITOTIC_SPINDLE-0.250
- PI3K_AKT_MTOR_SIGNALING-0.250
- MYC_TARGETS_V1-0.230
- UNFOLDED_PROTEIN_RESPONSE-0.230
- PROTEIN_SECRETION-0.180
- ALLOGRAFT_REJECTION-0.150
- DNA_REPAIR-0.150
- E2F_TARGETS-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R114 | — | — | 0.839 |
| 2 | SRR659013 | GTEX | — | 0.817 |
| 3 | TCGA-MV-A51V-01A-11R-A26T-07 | — | — | 0.780 |
| 4 | R110 | — | — | 0.761 |
| 5 | SRR1409305 | GTEX | — | 0.753 |
| 6 | MNG188 | — | — | 0.751 |
| 7 | ERR2208930 | — | — | 0.748 |
| 8 | TCGA-BH-A1ES-06A-12R-A24H-07 | — | C | 0.738 |
| 9 | SJEPD001521_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.733 |
| 10 | SRR5903552 | — | cohortA1 | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| HYPOXIA | 0.050 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |